Latest News

Novel Clinic Resulted in ‘Impressive’ Outcomes for Patients With Moderate to Severe Eczema


 

FROM PEDIATRIC DERMATOLOGY

Important model of care

Asked to comment on the results, pediatric dermatologist Moise L. Levy, MD, professor of internal medicine and pediatrics at the University of Texas at Austin, who was not involved with the study, characterized the MADP as an important model of care. “Multi-interdisciplinary care of such conditions is well-known to be of great help for patients and their families,” he told this news organization.

Dr. Moise L. Levy professor of pediatrics and medicine at the University of Texas at Austin Dell Medical Schoo

Dr. Moise L. Levy

“A key part of the ‘team’ is the family/patient engagement and shared decision-making. The use of visual aides to highlight components of care was likely of great use, as well,” he said. “All such interventions impact the disease, as well as associated problems, such as itch, sleep, and mental health. Importantly, such interventions, while known to be useful as demonstrated by the authors, take time, and relate to improved outcomes as noted by the date outlined by the authors.”

The study authors acknowledged certain limitations of the study, including the lack of a control group with single-specialty visits. “The real take-away is that taking the time to do more holistic assessments of health — with skin and allergy issues being discussed, and consistent education and messaging — helps make our medical interventions more successful, with both objective disease improvement and patient/family satisfaction,” Dr. Eichenfield said in the interview.

Pfizer and Sanofi provided financial support to MADP, and for the study. Dr. Eichenfield disclosed that he serves as a scientific adviser, consultant, and/or clinical trial investigator for AbbVie, Amgen, Aslan, Castle Biosciences, Dermavant, Eli Lilly and Company, Forté, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi-Genzyme, Trialspark, and UCB. Dr. Geng disclosed ties with Sanofi, Regeneron, Pfizer, and AbbVie, and is an adviser to Incyte, Galderma, Eli-Lilly, and LEO. The other authors reported having no disclosures. Dr. Levy disclosed ties with Abeona, Amgen, Arcutis, Castle Creek, Dusa Pharma, Krystal Bio, Novan, Regeneron, and Sanofi Genzyme. He is also an investigator for Janssen.

Pages

Recommended Reading

Dupilumab-associated lymphoid reactions require caution
Clinician Reviews
Pustular Eruption on the Face
Clinician Reviews
Review estimates acne risk with JAK inhibitor therapy
Clinician Reviews
AAD updates guidelines for managing AD with phototherapy and systemic therapies
Clinician Reviews
Tapinarof effective for AD in patients as young as 2 years
Clinician Reviews
Paradoxical Eczema Risk Low With Biologic Psoriasis Treatments
Clinician Reviews
‘Milestone’ Study Zeros in on 5-Year Safety Data From Upadacitinib Trials
Clinician Reviews
Expert Frames Factors to Consider Among Atopic Dermatitis Treatment Options
Clinician Reviews
Experimental Topical Drug Shows Promise for Atopic Dermatitis and Plaque Psoriasis
Clinician Reviews
US Dermatologic Drug Approvals Rose Between 2012 and 2022
Clinician Reviews